�Brunel University Researcher Suggests that Chemicals in Household Cleaning Products Explains Why Excessive Hygiene is Linked to Increased Asthma and AllergiesBrunel University Researcher Suggests that Chemicals in Household Cleaning Products Explains Why Excessive Hygiene is Linked to Increased Asthma and Allergies
Women world Health Organization use a lot of household cleaning products when they ar pregnant, or shortly after giving birth, are increasing their child's risk of developing asthma attack. That's according to the Avon Longitudinal Study of Parents of Children (ALSPAC, also known as Children of the Nineties), that recruited over 13,000 children from before nascency and has followed them to post 16.
The findings indicated that early life exposure to the chemicals contained in household cleansing products was linked to a 41% increase in a child's chances of developing bronchial asthma by the age of 7 geezerhood. During the study, a large number of other factors known to affect the onslaught of bronchial asthma, such as family history, were accounted for. The results thus present a possible chemical mechanism for the 'hygiene hypothesis', which suggests that children brought up with humbled exposure to bacteria and dust in the home in their early age are less likely to build an immunity to asthma later in life.
Dr. Alexandra Farrow, Reader at Brunel University's School of Health Sciences and Social Care and a
Friday, 22 August 2008
Tuesday, 12 August 2008
Radium
Artist: Radium
Genre(s):
Other
Rock
Discography:
Radium feat. Hellfish - Detox
Year:
Tracks: 15
Inhuman Full Album
Year:
Tracks: 34
Intelligent glowering bikers Radium evolved from vocalist Tabatha Predovich's premature work in a series of musical projects from Minneapolis to London and eventually Detroit. In Minneapolis in 1990, Predovich performed with the improvisational unit Velvet Rat. Her go through and exposure with the band was sufficiency to draw the interest of the band Elysium, and she resettled to England with the band in the outpouring of 1993. She wrote, recorded and toured with the band for trey long time, finally lapsing to the U.S. in 1995, endpoint up in Detroit. Predovich formed Radium to positive vital clap, just the first base incarnation disbanded within a yr of formation. In decree to fulfill the remaining shows, the singer enlisted guitar player Rich Patterson (the Resonators), bassist Dave Krofchok (other keyboardist for Discipline), and drummer David Below (previously of India Green). These "temporary" performers shortly evolved into Radium version 2.0. Second guitar player Dave Johnson (once of Caelum Bliss and Brilliant) joined the band vI months later. Their helen of Troy Wills, atmospherical EP Tongue of the Ocean was released in 2001.
Wednesday, 6 August 2008
Jordan 'Not Welcome' at Polo Contest
British glamour model Jordan was left reeling after being told she was not
Lagwagon
Artist: Lagwagon
Genre(s):
Rock: Punk-Rock
ROck: Alternative
Discography:
Resolve
Year: 2005
Tracks: 12
Blaze
Year: 2003
Tracks: 15
Let's Talk About Feelings
Year: 1998
Tracks: 12
![Double Plaidinum [VINYL]](http://img.mp3fiesta.com/covers/18/18229/alb_73507_th.jpg)
Double Plaidinum [VINYL]
Year: 1997
Tracks: 12
Trashed
Year:
Tracks: 14
Duh
Year:
Tracks: 14
Southern California punks Lagwagon formed in the small township of Goleta in 1990. Originally dubbed Section 8, Lagwagon's lineup often fluctuated during their formative period and, by the time of the band's 1992 debut, Duh, was comprised of isaac Merrit Singer Joey Cape, guitarists Chris Flippin and Shawn Dewey, bassist Jesse Buglione, and drummer Derrick Plourde. Trashed followed two days afterward, and in 1995 Lagwagon returned with Hoss; Plourde left the band shortly later on and was replaced by ex-Rich Kids on LSD drummer Dave Raun. Former Posies guitar player Ken Stringfellow likewise replaced Dewey in time for Lagwagon's succeeding endeavour, 1997's Doubled Plaidinum; he before farseeing foregone as well, and another Rich Kids caustic potash alum, guitar player Chris Rest, was on gameboard for 1998's Let's Talk About Feelings. It took quint days to record 2003's Blaze -- Let's Talk About Leftovers, a compilation of B-sides, outtakes, and songs both old and new appeared in 2000, simply it constitute the group as dependable as of all time, touting anthems both political and personal. Cape then issued a split acoustic album, capably highborn Acoustic, with No Use for a Name's Tony Sly in 2004. Both Unrecorded in a Dive and Resolve were released in 2005. The latter album was consecrated to drummer Plourde; woefully, he had attached felo-de-se earlier in the year.
BioCurex Files New RECAF Patent - New Methods For Tumor Imaging And Therapy Based On RECAF
�BioCurex Inc. has announced that it has filed a newfangled patent application to protect certain
methods of purifying and detecting RECAF in bodily fluids. The patent application
too includes what the party believes - based on available data - to be
new methods for tumor imaging and therapy based on RECAF.
The patent applications programme has been filed as a provisionary patent application. This
means that the patent application remains undisclosed for up to 18 months at the
owner's discretion, so providing one more year of protection, and, assumptive the
patent application is granted, thus providing farther RECAF applied science
protection for another 21 years.
This patent application contains critical methods necessary for manufacturing
RECAF tests as intimately as for the generation of synthetic products to be secondhand to
target RECAF in vivo (inside the body). These products buns be manufactured at
blue cost, in highly pure form and without the need to use biological systems;
thence eliminating the possibility of carrying infective diseases to the
recipients.
As a result of the trade protection provided by this young patent lotion, the
company has confiscate its former patent coating in Japan, where differences
in patent law as compared to the USA and the EU, make resulted in unanticipated
resistance to approval. BioCurex holds granted patents in the USA, the European
Union, Russia, Australia, Norway and China at this time.
The raw application volition soon be extended through the Patent Cooperation Treaty
to the most populated and developed countries with highest market potential, as
we own done antecedently.
Dr. Moro, BioCurex's CEO stated: 'This new patent application is the solution of
various years of intense work and it reflects the value added to our company
resulting from that investment in time and money. We - and our licensees - make
been exploitation technology contained in our issued patents for some time now, in our
daily ferment. There ar other improvements that will be the subject of new patent
applications to be filed in the near future. This strategy is intended to stake
the RECAF technology with a figure of patent claims in a direction that will prevent
others from circumventing our patents as advantageously as extending the tribute period
of our technology. '
The additional auspices, offered by the claims related to blood tests in this
new patent application, is extended to our electric current licensees. This will extend
the term of our licensing agreements and consequently enhance our royalties.
However, there are also other claims related to different fields and applications
non encompassed in our stream agreements and they can be freely licensed to new
recognised licensees.
About BioCurex
BioCurex, Inc. is a biotechnology company that is developing products based on
patented/proprietary engineering in the areas of cancer diagnosis, imaging and
therapy. The technology identifies a cancer marker known as RECAFtm, which is
found on malignant cells from a variety of cancer types but is absent in most
normal or benign cells.
BioCurex has sign-language licensing agreements for its cancer detecting blood tests
with Abbott Laboratories and with Inverness Medical Innovations (for farther
information on these agreements click here.
The crab marker RECAFTM has emerged as a potential biomarker that may be useful
in the development of new cancer the Crab diagnostics tests. Preliminary studies from the
investigators at BioCurex have reported a high grade of clinical sensitivity and
specificity for RECAF in many of the most common cancers, including prostate,
breast, colorectal, lung and others.
The Company has not authorised the outlet of this information in any form that
contravenes the Communication Act and will non be responsible for unsolicited
massive dispersion of this material by e-mail or facsimile by unauthorized parties.
Statements in this press release, which are not historical facts, are
'forward-looking statements'' within the meaning given to that term in the
Private Securities Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created thereby. Since
these statements involve risks and uncertainties and are subject to change at
whatsoever time, the Company's actual results could differ materially from expected
results.
Biocurex
More info
methods of purifying and detecting RECAF in bodily fluids. The patent application
too includes what the party believes - based on available data - to be
new methods for tumor imaging and therapy based on RECAF.
The patent applications programme has been filed as a provisionary patent application. This
means that the patent application remains undisclosed for up to 18 months at the
owner's discretion, so providing one more year of protection, and, assumptive the
patent application is granted, thus providing farther RECAF applied science
protection for another 21 years.
This patent application contains critical methods necessary for manufacturing
RECAF tests as intimately as for the generation of synthetic products to be secondhand to
target RECAF in vivo (inside the body). These products buns be manufactured at
blue cost, in highly pure form and without the need to use biological systems;
thence eliminating the possibility of carrying infective diseases to the
recipients.
As a result of the trade protection provided by this young patent lotion, the
company has confiscate its former patent coating in Japan, where differences
in patent law as compared to the USA and the EU, make resulted in unanticipated
resistance to approval. BioCurex holds granted patents in the USA, the European
Union, Russia, Australia, Norway and China at this time.
The raw application volition soon be extended through the Patent Cooperation Treaty
to the most populated and developed countries with highest market potential, as
we own done antecedently.
Dr. Moro, BioCurex's CEO stated: 'This new patent application is the solution of
various years of intense work and it reflects the value added to our company
resulting from that investment in time and money. We - and our licensees - make
been exploitation technology contained in our issued patents for some time now, in our
daily ferment. There ar other improvements that will be the subject of new patent
applications to be filed in the near future. This strategy is intended to stake
the RECAF technology with a figure of patent claims in a direction that will prevent
others from circumventing our patents as advantageously as extending the tribute period
of our technology. '
The additional auspices, offered by the claims related to blood tests in this
new patent application, is extended to our electric current licensees. This will extend
the term of our licensing agreements and consequently enhance our royalties.
However, there are also other claims related to different fields and applications
non encompassed in our stream agreements and they can be freely licensed to new
recognised licensees.
About BioCurex
BioCurex, Inc. is a biotechnology company that is developing products based on
patented/proprietary engineering in the areas of cancer diagnosis, imaging and
therapy. The technology identifies a cancer marker known as RECAFtm, which is
found on malignant cells from a variety of cancer types but is absent in most
normal or benign cells.
BioCurex has sign-language licensing agreements for its cancer detecting blood tests
with Abbott Laboratories and with Inverness Medical Innovations (for farther
information on these agreements click here.
The crab marker RECAFTM has emerged as a potential biomarker that may be useful
in the development of new cancer the Crab diagnostics tests. Preliminary studies from the
investigators at BioCurex have reported a high grade of clinical sensitivity and
specificity for RECAF in many of the most common cancers, including prostate,
breast, colorectal, lung and others.
The Company has not authorised the outlet of this information in any form that
contravenes the Communication Act and will non be responsible for unsolicited
massive dispersion of this material by e-mail or facsimile by unauthorized parties.
Statements in this press release, which are not historical facts, are
'forward-looking statements'' within the meaning given to that term in the
Private Securities Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created thereby. Since
these statements involve risks and uncertainties and are subject to change at
whatsoever time, the Company's actual results could differ materially from expected
results.
Biocurex
More info
Subscribe to:
Posts (Atom)